- Previous Close
2,637.88 - Open
2,637.88 - Bid 2,450.00 x 1700
- Ask --
- Day's Range
2,637.88 - 2,637.88 - 52 Week Range
1,730.00 - 2,915.60 - Volume
258 - Avg. Volume
259 - Market Cap (intraday)
4.575T - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
17.30 - EPS (TTM)
152.47 - Earnings Date Apr 16, 2025
- Forward Dividend & Yield 48.34 (1.83%)
- Ex-Dividend Date Apr 15, 2025
- 1y Target Est
--
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
www.abbott.comRecent News: ABT.MX
View MorePerformance Overview: ABT.MX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ABT.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ABT.MX
View MoreValuation Measures
Market Cap
4.30T
Enterprise Value
4.44T
Trailing P/E
17.31
Forward P/E
25.71
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.51
Price/Book (mrq)
4.81
Enterprise Value/Revenue
5.31
Enterprise Value/EBITDA
20.66
Financial Highlights
Profitability and Income Statement
Profit Margin
31.95%
Return on Assets (ttm)
6.06%
Return on Equity (ttm)
30.91%
Revenue (ttm)
41.95B
Net Income Avi to Common (ttm)
13.35B
Diluted EPS (ttm)
152.47
Balance Sheet and Cash Flow
Total Cash (mrq)
7.97B
Total Debt/Equity (mrq)
31.89%
Levered Free Cash Flow (ttm)
5.61B